KR101552821B1 - Enzymatic hydrolized Formica truncicola extract powder having vasodilatation, sexual function improvement and anti-inflammatory effect - Google Patents
Enzymatic hydrolized Formica truncicola extract powder having vasodilatation, sexual function improvement and anti-inflammatory effect Download PDFInfo
- Publication number
- KR101552821B1 KR101552821B1 KR1020150112211A KR20150112211A KR101552821B1 KR 101552821 B1 KR101552821 B1 KR 101552821B1 KR 1020150112211 A KR1020150112211 A KR 1020150112211A KR 20150112211 A KR20150112211 A KR 20150112211A KR 101552821 B1 KR101552821 B1 KR 101552821B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- truncicola
- formica
- ethanol
- powder
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 73
- 239000000843 powder Substances 0.000 title claims abstract description 68
- 230000036299 sexual function Effects 0.000 title claims abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 18
- 241001251054 Formica truncorum Species 0.000 title abstract description 14
- 230000002255 enzymatic effect Effects 0.000 title abstract description 11
- 230000006872 improvement Effects 0.000 title description 3
- 206010047141 Vasodilatation Diseases 0.000 title description 2
- 230000024883 vasodilation Effects 0.000 title description 2
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 29
- 102000004190 Enzymes Human genes 0.000 claims abstract description 26
- 108090000790 Enzymes Proteins 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 12
- 239000004375 Dextrin Substances 0.000 claims abstract description 10
- 229920001353 Dextrin Polymers 0.000 claims abstract description 10
- 235000019425 dextrin Nutrition 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 235000021067 refined food Nutrition 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 24
- 241000257303 Hymenoptera Species 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 15
- 241000254158 Lampyridae Species 0.000 claims description 12
- 210000003056 antler Anatomy 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 239000012670 alkaline solution Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 102000035195 Peptidases Human genes 0.000 claims description 7
- 230000001857 anti-mycotic effect Effects 0.000 claims description 7
- 239000002543 antimycotic Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 45
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003513 alkali Substances 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 238000005507 spraying Methods 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 86
- 210000004027 cell Anatomy 0.000 description 22
- 108010057466 NF-kappa B Proteins 0.000 description 21
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 21
- 210000003556 vascular endothelial cell Anatomy 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 230000002421 anti-septic effect Effects 0.000 description 14
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 12
- 229960004588 cilostazol Drugs 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 229940121375 antifungal agent Drugs 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 230000000843 anti-fungal effect Effects 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 8
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000002460 smooth muscle Anatomy 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 230000002790 anti-mutagenic effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 230000003373 anti-fouling effect Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229910052787 antimony Inorganic materials 0.000 description 4
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000005226 corpus cavernosum Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000007758 mating behavior Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001856 erectile effect Effects 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GLKCOBIIZKYKFN-UHFFFAOYSA-N 2-aminopteridine-4,7-diol Chemical compound N1=CC(O)=NC2=NC(N)=NC(O)=C21 GLKCOBIIZKYKFN-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- PEQMCTODPDZUDG-UHFFFAOYSA-N antimony;ethanol Chemical compound [Sb].CCO PEQMCTODPDZUDG-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102000008125 NF-kappa B p52 Subunit Human genes 0.000 description 1
- 108010074852 NF-kappa B p52 Subunit Proteins 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000517830 Solenopsis geminata Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002072 anti-mutant effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002519 antifouling agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000029082 maternal behavior Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Images
Classifications
-
- A23L1/30—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Insects & Arthropods (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
(A) immersing and drying the dried firefly in an aqueous alkaline solution; (b) adding an aqueous ethanol solution to the firewood taken out in step (a), extracting it, filtering and separating the ethanol extract; (c) separating the ethanol extract of step (b) and adding water and proteolytic enzyme to the remaining firewood to extract the extract; (d) mixing the extracted extract of step (c) and the ethanol extract of step (b), filtering and drying; And (e) adding dextrin and water to the dry seaweed extract of step (d) and spray drying the seaweed extract. The method of
Fireworks ( Formica truncicola ) is a species of ants belonging to the ants. The body has a dark red color and a light yellow hairs throughout the body. Fire ants live in rotten trees, soil, and stones in Korea, Japan, China, Taiwan, and Russia, and do not live under live trees. Fireworms are widely distributed inland in Korea and fewer in the south. Currently, there are about 60 species of ants in 1, 26, and 60 species including ants and fire ants in Korea.
The anemia is known as a fire ant, and its efficacy is known to be effective for joint pain, cardiovascular disease, respiratory system bronchitis, urinary system, digestive system, nervous system, pulmonary tuberculosis, It is an important medicinal drug that has been used mainly when the wound is not healed. 100 grams of dried ants contain over 70 grams of protein and contain 28 free amino acids and 8 amino acids, including isoxanthopterin, biotin, vitamin B2, 2-amino-6-hydro And cyperteridine.
The ant ingredient contains a venomous solution in the gall bladder, the most important of which is formic acid, and contains 90% of the antialdehyde. The antimutant is known to have the above nutritional elements and efficacy, but the formic acid which shows the toxicity of fire ants is strong enough to be 20 times that of Japanese royal family, and it is difficult to completely neutralize the formic acid in general processing, The development of processed food using
Korean Patent Laid-Open Publication No. 2004-0023459 discloses a known technology for manufacturing health supplement foods by mixing fire antiseptics with various medicines and Korean Patent No. 1136090 discloses an antifungal agent There is known a functional food including a liquid obtained by mixing and then heating a medicinal herb, and Korean Patent No. 1102831 discloses a method of manufacturing a health food which is produced by fire antibiotics and various natural medicines in the form of a bath.
However, the prior art discloses only simple addition of an antidote to a food composition, but specific and scientific contents and data such as an antimutagenic sexual function improvement and anti-inflammatory effect are not disclosed and are different as in the present invention.
The present invention has been made in view of the above-mentioned needs, and it is an object of the present invention to provide an antifungal agent which can effectively neutralize formic acid contained in fire ants, thereby solving the problems of human toxicity during ingestion, The object of the present invention is to establish a method for producing an antimicrobial extract powder having enhanced sexual function and anti-inflammatory effect by extracting and then drying the fire ants.
In order to solve the above-described problems, the present invention provides a method for producing a firefly, comprising the steps of: (a) immersing a dried firefly in an aqueous alkaline solution and then taking it out; (b) adding an aqueous ethanol solution to the firewood taken out in step (a), extracting it, filtering and separating the ethanol extract; (c) separating the ethanol extract of step (b) and adding water and proteolytic enzyme to the remaining firewood to extract the extract; (d) mixing the extracted extract of step (c) and the ethanol extract of step (b), filtering and drying; And (e) adding dextrin and water to the dry antifoulant extract of step (d) and spray-drying the antifouling extract of step (d). to provide.
In addition, the present invention provides a fragrant enzyme decomposition extract powder prepared by the above method.
In addition, the present invention provides a processed food containing the above cracked enzyme decomposition extraction powder.
The present invention effectively cleanses the formic acid contained in the fire ants through an antifouling pretreatment process, efficiently extracts the functional components contained in the fire ants, and improves the sexual function by drying and pulverizing the extracted extract, , There is an advantageous effect that the extracted powder can be used for food, pharmaceutical industry and the like.
FIG. 1 is a graph comparing the amount of NO production in mouse macrophages (RAW 267.4) according to the antiseptic powder treatment.
(A) LPS (2 ㎍ / ㎖) + Fire Fighting Enzymatic Extraction Powder Treatment, (A-1)
Figure 2 compares the NF-κB signaling pathway in mouse macrophages (RAW 267.4) following antimony powder treatment.
DMSO: dimethyl sulfoxide, Cilostazol: Cilostazol, red A: fire-cracking enzyme decomposition powder, red B: antimony ethanol extract powder
FIG. 3 is a graph comparing the NO production amount after incubation for 12 hours in mouse vascular endothelial cells (MOVAS) according to the antiseptic powder treatment.
HA: firefly enzyme decomposition extraction powder, HB: antiseptic ethanol extract powder
Figure 4 compares the NF-κB signal transduction mechanism in mouse vascular endothelial cells (MOVAS) following an antiseptic powder treatment.
Figure 5 compares the NF-κB signaling pathway in human vascular endothelial cells (HUVEC) following an antiseptic powder treatment.
DMSO: dimethyl sulfoxide, Cilo: Cilostazol, HA: firepot enzyme decomposition extraction powder, HB: antiseptic ethanol extract powder in FIGS. 4 to 5.
FIG. 6 is a graph comparing the activities of production of endothelial nitric oxide synthase (eNOS) according to the antifungal treatment in mouse vascular endothelial cells (MOVAS) and human vascular endothelial cells (HUVEC).
Red A: Fire Fighting Enzyme Decomposition Extract Powder, Red B: Antimony Ethanol Extraction Powder
In order to achieve the object of the present invention,
(a) immersing the dried firefly in an aqueous alkaline solution and then taking it out;
(b) adding an aqueous ethanol solution to the firewood taken out in step (a), extracting it, filtering and separating the ethanol extract;
(c) separating the ethanol extract of step (b) and adding water and proteolytic enzyme to the remaining firewood to extract the extract;
(d) mixing the extracted extract of step (c) and the ethanol extract of step (b), filtering and drying; And
(e) adding dextrin and water to the dry antler extract of step (d) and spray-drying the antler extract; and do.
In the method for producing the fragrant enzyme decomposition extraction powder of the present invention, the aqueous alkaline solution of step (a) may be an aqueous 0.1 to 10% by weight alkali solution preferably having a pH of 8 to 9, more preferably 0.1 % Alkali aqueous solution. The alkali used in the aqueous alkali solution is preferably at least one selected from the group consisting of sodium bicarbonate, sodium acetate, potassium acetate, sodium citrate, potassium citrate and potassium carbonate, more preferably sodium bicarbonate . Through the alkali treatment as described above, the formic acid contained in the fire ants could be partially neutralized.
In addition, in the method for producing the fragrant enzyme decomposition extraction powder of the present invention, the protease of step (c) may be an alkaline, but is not limited thereto.
In order to further improve the anti-inflammatory effect of the antirheumatic powder in the method for producing ungermant enzymatic decomposition extraction powder of the present invention, (f) a step of adding ethanol to the spray dried antifungal enzyme decomposition extraction powder followed by extraction, More specifically, 60 to 80% (v / v) ethanol is mixed in the ratio of 0.8 to 1.2: 8 to 12 (w: v) to the spray-dried antibiotic decomposition extract powder, More specifically, 70% (v / v) ethanol was mixed at a ratio of 1:10 (w: v) to spray-dried antibiotic-decomposed enzyme-extracted powder, and then the mixture was extracted three times It can be repeatedly extracted.
The method for producing an ungermant enzyme decomposition extraction powder of the present invention is more specifically
(a) immersing the dried firefly in an aqueous alkaline solution having a pH of 8 to 9 for 50 to 70 minutes and then taking out the same;
(b) adding an aqueous 45 to 55% (v / v) ethanol solution to the fire ants taken in step (a), extracting the mixture at 50 to 70 ° C for 8 to 12 hours, filtering and separating the ethanol extract;
(c) extracting the ethanol extract of step (b), adding water and proteolytic enzyme to the remaining anthrax extract, extracting it at 40 to 50 ° C for 65 to 80 hours while maintaining the pH at 8 to 9;
(d) mixing the extracted extract of step (c) and the ethanol extract of step (b), filtering and drying; And
(e) adding dextrin and water to the dry antimycotic extract of step (d) to adjust the brix to 25 to 35 brix, bringing the temperature to 170 to 190 DEG C and the air temperature to 100 to 120 DEG C at a rate of 0.2 to 0.4 L / Spray drying,
More specifically,
(a) immersing the dried firefly in an aqueous alkaline solution of pH 8.5 for 60 minutes and then taking it out;
(b) adding 50% (v / v) ethanol aqueous solution to the fire ants taken in step (a), extracting at 60 ° C for 10 hours, filtering and separating the ethanol extract;
(c) separating the ethanol extract of step (b), adding water and proteolytic enzyme to the remaining anthrax extract, and extracting it at 40 to 50 ° C for 72 hours while maintaining the pH at 9;
(d) mixing the extracted extract of step (c) and the ethanol extract of step (b), filtering and drying; And
(e) spray-drying at a rate of 0.3 L per minute at an inlet temperature of 180 ° C and an air-ventilation temperature of 110 ° C by adjusting dextrin and water to 30 brix by adding the dried antler extract of step (d) have.
The present invention also provides a fire-fighting enzyme decomposition extraction powder having the sexual function and anti-inflammatory effect prepared by the above method. The antifouling enzyme extracted powder of the present invention can extract functional ingredients more effectively than conventional antifouling powders and can provide an antifungal powder having improved sexual function and anti-inflammatory effect.
The present invention also provides a processed food containing the above cracked enzyme decomposition extraction powder. There is no particular limitation on the kind of the processed food. Examples of the food to which the above cracked enzyme decomposition extraction powder can be added include dairy products including pie, tablet, meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, all of which include processed foods in a conventional sense.
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
Manufacturing example 1: Preparation of fire-cracking enzymatic decomposition extraction powder
(a) 1 kg of dry fire ants were immersed in a 0.1% aqueous solution of sodium bicarbonate of pH 8.5 for 1 hour and then recovered.
(b) 5 kg of a 50% aqueous ethanol solution was added to the recovered ants of the step (a), stirred at 60 ° C for 10 hours, filtered and the ethanol extract was separated.
(c) 5 kg of purified water was added to the remaining antimony ethanol-extracted leaves, and 5 g of protease (alkalazine, Novozymes) was added while maintaining the pH at 9 to 40 ° C at 50 ° C. The mixture was stirred for 72 hours The enzyme was degraded.
(d) The extracted extract of step (c) and the ethanol extract of step (b) were mixed and filtered with a 200 mesh microfilter, followed by vacuum drying.
(e) 50% (w / w) of dextrin is added to the dried antler extract of step (d), and purified water is further added thereto to adjust the concentration to 30 brix. And spray-dried at a rate of 0.3 L per minute to obtain a fire-extinguishing enzyme-extracted powder.
Comparative Example 1: Manufacture of antimony powder
50% (w / w) of dextrin was added to powder obtained by pulverizing 1 kg of dried fire ants, and further purified water was added thereto to adjust to 30 brix. The powder was adjusted to have a draw temperature of 180 ° C and an air temperature of 110 ° C, L to produce antifungal powders.
Experimental Method
1. Sexual Enhancement Experiment
1) Sexual function experiment
Male sexually active male New Zealand Hight Rabbit (Samutobi Bio Korea), which has a similar structure and physiological erectile mechanism to the penile corpus cavernosum of the human body, was tested with the test animals by the following method Were used for the experiment.
That is, the animals were anesthetized by inhalation of ether, and the penis was excised to separate the cavernosal smooth muscle from the low-temperature Krebs-Henseleit's solution, which was supplied with a mixture of 95% oxygen and 5% carbon dioxide Respectively. 2 x 2 x 2 mm sections were prepared from the separated cavernosal smooth muscle and fixed in an organ bath containing Krebs hexellate solution.
One end of the section was fixed to the lower part of the tissue container and the other end was connected to a power shrinkage recorder to record the movement state of the cavernosal smooth muscle. The Krebs hexenylate solution in the tissue container was maintained at 37 占 폚 and the oxygen mixed gas was continuously supplied. The smooth muscle slices produced by the above method induced contraction by phenylephrine (1 × 10 -5 M) and the existence of endothelial cells was confirmed by the presence or absence of relaxation by acetylcholine (Acetycholine). After removal of endothelial cells, only a sample with relaxation of less than 10% of acetylcholine relaxation was used as a smooth muscle slice with endothelial cells removed. The tip of the clamped rabbit corpus cavernosum was connected to an isometric force-displacement tranducer (FT03, Grass, AD instrumuent, Colorado springs, Co. USA)
In order to confirm the effect of the antimicrobial powder on the basic tension of the cavernosal sections, the stability of the corpus cavernosum tissue was stabilized and the concentrations of 0.1 mg / ㎖, 0.5 mg / ㎖, 1 mg / Ml, and the change of the tension and the change of the amplitude were measured with the passage of time.
2) Maternal behavior change
In order to examine the effective doses of the fragrant enzyme decomposition extract powder according to the present invention, 50 mice of SD rats and 20 females were sprayed with 1 mg / kg, 10 mg / kg, 100 mg / kg was taken for 1 day, and the number of mating, number of inserting, mating behavior regression time were measured for 4 weeks.
2. Anti-inflammatory effect
(1) Production of ethanol extract powder
100 g of the fragrant enzyme-decomposing extracted powder of Preparation Example 1 was added to 1,000 ml of a 70% ethanol solution, and the mixture was heated under reflux for 2 hours. This process was repeated two more times to obtain an extract. The extracted extract was filtered, and the filtrate was centrifuged at 5,000 × g for 30 minutes to obtain supernatant. The supernatant was taken in a rotary vacuum concentrator (EYELA, Japan), concentrated under reduced pressure, and lyophilized in a freeze dryer to obtain 7.86 g of the extract.
(2) In vitro experiments
1) Preparation of vascular endothelial cells
For in vitro experiments to confirm the anti-inflammatory effect of antimicrobial powder, mouse vascular endothelial cells (MOVAS, mouse vascular endothelial cells) and human vascular endothelial cells (HUVEC, human umbilical vein endothelial cells) Respectively.
2) Measurement of NO (Nitric Oxide) production
Antiserum extract was dissolved in dimethyl sulfoxide (DMSO, Sigma Chem, CO.) To a final concentration of 0.05% and used by filtration sterilization with a filter (0.02 ㎛ pore size, Millipore). The concentrations of the samples were 100, 50, 25, 12.5, 6.25, 3.125, 1.5625 and 0.78125 ㎍ / ㎖, which were determined through preliminary experiments. The grease reagent, which is a reagent for measuring NO production, is prepared by adding Solution A (0.2% Naphthylethylene diamine dihydrochloride in DW) and Solution B (2% Sulfonylamide in 5% H 3 PO 4 ) and stored in a cool dark place. Solution was mixed at a ratio of 1: 1 and a mixed solution was used. 100 μl of the culture supernatant was dispensed into a 96-well plate, and 100 μl of the mixed solution was dispensed. The absorbance at 540 nm was measured using an ELISA reader. The standard calibration curve was 0 to 80 μM Lt; / RTI >
3) Western blot analysis
Cells were lysed with lysis buffer (20% SDS, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM iodoacetoamide, 1 mM leupeptin, 1 mM antipain, 0.1 mM sodium orthovanadate, 5 mM sodium fluoride) Proteins were quantified using a DC protein assay kit from Hercules, CA, USA. 20 to 60 占 퐂 of proteins were separated by size by SDS-PAGE, transferred to nitrocellulose membrane, and then incubated with blocking solution at room temperature for one hour. Then, the cells were incubated with primary antibody at 4 ° C for one day, and cultured at room temperature for 2 hours using a secondary antibody conjugated with HRP (horseradish peroxidase). Antibody-bound proteins were developed by exposure to X-ray film using an ECL kit (Perkin Elmer Life and Analytical Science, Boston, Mass., USA).
4) NO (Nitric Oxide) analysis
LNCaP prostate cancer cell line cells were divided into 24 well plates at a density of 1 x 10 4 cells / ml, stabilized for 24 hours, treated with cilostazol and antler extract, and cultured for 12 hours and 24 hours, respectively. The cell culture was separated from each well, placed in a 1.5 ml tube, refrigerated, and analyzed for NO. 50 μl of the cell culture was taken and mixed with 50 μl of a grease reagent (1% sulfanilamide / 0.1% N- (1-naphthyl) -ethylenediamine dihydrochloride / 2.5% H 3 PO 4 ) and dispensed into a 96-well plate. After 5 to 10 minutes of incubation in the dark room, the NO content was measured at 530 nm in an ELISA reader after 30 minutes of change to purple / magenta, and the NO concentration was calculated based on the standard curve of sodium nitrite (NaNO 2 ) .
(3) Effect on anti-inflammation in RAW264.74 cell line
1) Cell line and cell culture
The mouse macrophage cell line (RAW264.7) was purchased from Seoul National University, Seoul, Korea. Mouse macrophage cell line (RAW264.7) supplemented with 10% FBS and 1% antibiotics added to the temperature of 37 ℃ in MEM medium with 5% CO 2 condition CO 2 that is maintained And cultured in an incubator (Forma Sci, USA).
2) RAW264.7 Analysis of macrophage culture and NO production
The culture medium (37 ° C, humidified, 5% CO 2 /95% air environment) was placed in a 24-well culture plate with 2 ml of DMEM medium containing 10% FBS and 2 × 10 5 cells / well of RAW 264.7 cells ), And then the supernatant was removed. Then, cilostazol (10 μg / ml) treated with LPS at a concentration of 2 μg / ml and 4 μg / ml and the antiserum extract (10, 50, 100 μg / Ml) and then cultured again. The supernatant was separated and stored in a freezer. ELISA was performed by using Mouse NO (Intron, Korea) ELISA kit. 100 쨉 l of cilostazol and supernatant were added to each well according to the manufacturer's instructions. The wells were incubated for 2 hours and then incubated at room temperature. The grease reagent, which is a reagent for measuring NO production, is prepared by adding Solution A (0.2% Naphthylethylene diamine dihydrochloride in DW) and Solution B (2% Sulfonylamide in 5% H 3 PO 4 ) and stored in a cool dark place. Solution was mixed at a ratio of 1: 1 and a mixed solution was used. 100 μl of the culture supernatant was dispensed into a 96-well plate, and 100 μl of the mixed solution was dispensed. The absorbance at 540 nm was measured using an ELISA reader. The standard calibration curve was 0 to 80 μM Lt; / RTI >
3) Western blot analysis
Western blot analysis was performed using the anti-inflammatory factor NF-kB antibody in order to determine whether the antiserum extract was involved in the anti-inflammatory mechanism in the RAW264.7 cell line. The RAW264.7 cell line was divided into 6-well plates at 5 × 10 6 cells / ml and cultured for 24 hours. Antifungal extracts were treated at 10, 50 and 100 μg / ml, / Ml and then cultured. After incubation, the cells were washed with cold PBS, and cells were obtained with a scraper and centrifuged to discard the supernatant. Whole cell lysate was reacted with 100 μl of Lysis buffer (980 μl of RIPA buffer + 100 μl of protease inhibitor cocktail + 10 μl of PMSF 100 mM) for 15-20 minutes on ice, and the supernatant was obtained. Cytoplasmic fractions were collected by centrifugation using ice / cytoplasmic extraction kit (Active motif, USA) for 15 min on ice. Lysis buffer was added to the nuclei remaining in the tube, reacted on ice for 30 seconds, and centrifuged to obtain a nuclear fraction. The obtained protein was quantified by BCA protein determination method. A 10% SDS-PAGE gel was prepared, filled with running buffer, pre-run for 20 minutes, the protein was diluted with a loading buffer and boiled for 5 minutes in boiling water, I released this twist. The first blank of the gel was floated, the protein marker was inserted in the second column, and the sample was added from the next column to 120V. The densified gel was cut to size and immersed in a transfer buffer for 20 minutes, during which time the membrane was cut to the size of the gel and pre-soaked in transfer buffer. The gel and the membrane were closely adhered, then filled with transfer buffer, ice was not added, and the protein was transferred to the membrane at 150V for 1 hour and 30 minutes. Protein-transferred membranes were blocked with 5% skim milk (in TBS / T buffer) for 1 hour. As a primary antibody, goat anti-iNOS was reacted at 4 ° C for one day, and all primary antibodies used were those from Santa Cruz Biotechnology (Santa Cruz, Calif.). The next day, the secondary antibody was reacted for 1 hour at room temperature using anti-rabbit IgG (Amersham, Buckinghamshire, UK) and anti-goat IgG (Dako, Glostrup, Denmark). The membrane was reacted with a detection solution (Amersham, USA), and the membrane was lightly dried and transferred to a film to emit light. The film was immersed in the developing solution and developed, fixed on a fixing solution and dried. The band densities of the results were compared with those of YY-1 using Image-Rab densitometer (Bio-Rad, CA, USA).
4) Statistical analysis
Statistical analysis of all experimental results was performed using SAS statistical program. The results were expressed as mean value and standard error, and statistical significance ( p <0.05) was verified with ANOVA.
Example 1: Measurement of sexual function improvement by antiseptic powder treatment
To confirm the effect of the antifungal powder on the basic tension of the penile corpus cavernosum, the motility of penile cavernosal tissues was stabilized. When the tension was maintained constant, Table 1 shows the results of confirming the degree of enhancement of erection according to the concentration of the powder using the difference in the lowest point at which the smooth muscle of the penile cavernosal smooth muscle was relaxed against the peak at which the penile cavernosum smooth muscle was contracted by phenylephrine. As a result, it was confirmed that the antifungal enzyme extract of Preparation Example 1 according to the present invention can enhance the erectile power of the penis compared with the antifungal powder of Comparative Example 1. [
As a result of observing mating behavior change, the mating frequency, mating behavior regression time, and number of insemination were significantly higher in the 10 mg / kg fed group and 100 mg / kg fed group than in the control group Significant results were observed (Table 2).
Example 2: Mouse In the macrophage line (RAW 264.7) Anti-inflammatory effect of antler extract
(1) Measurement of NO production in mouse macrophages (RAW264.7 cell line)
NO reacts very quickly with lipid alkoxyl, a peroxyl radical intermediate, with or without an enzyme, to produce nitrification intermediates. NO is converted from a high concentration to a reactive oxidant causing pathological damage to the cell. LPS is a bacterial endotoxin that when administered to macrophages produces an inflammatory response mediator, such as inflammatory cytokines and NO, leading to pathological responses.
To investigate the effect of antimycotic extract and Cilostazol on NO production in RAW264.7 macrophages, RAW264.7 macrophages were treated with various concentrations of antiseptic extract and cilostazol (10 ㎍ / ㎖) as a positive control ) And stimulated with LPS. After 24 hours, the production of inflammatory cytokine NO was measured by ELISA.
FIG. 1 (A) shows the anti-inflammatory effect of the extract of ungulate enzymatic decomposition. As a result, the NO production amount measured by stimulation with
1 (A-1) shows the anti-inflammatory effect of the extract of the fire-fighting enzyme. As a result, the amount of NO produced by stimulation with
FIG. 1B shows the results of observation of the anti-inflammatory effect of the ethanol extract of ungulate ethanol. As a result, the NO production amount measured by stimulation with 2 μg / ml of LPS in RAW264.7 macrophages was higher than that of the normal group (RAW264.7, Normal) Treated group (LPS) significantly increased. The positive control group, cilostazol, showed a statistically significant decrease in NO production compared to the control (LPS) ( p <0.001). The amount of NO produced in the experimental group treated with antimutagenic ethanol extract was decreased in a concentration - dependent manner at 50, 100 ㎍ / ㎖ ( p <0.01) compared to the control (LPS).
Also, B-1 of FIG. 1 shows the anti-inflammatory effect of the ethanol extract of the antiseptic ethanol. As a result, the NO production measured by stimulation with
From the above results, it is considered that the antimutagenic extract powder inhibits the NO production directly involved in the inflammatory reaction.
(2) NF-κB signal transduction mechanism in mouse macrophage (RAW264.7) by firefly extract
NF-κB consists of five constitutive proteins (NF-κB1 [p105 / p50], NF-κB2 [p100 / p52], RelA / p65, RelB and c-Rel) And RHD (Rel-homology domain) composed of amino acids. This domain plays an important role in the NF-κB signaling pathway involved in homotypic or heterodimer formation of the NF-κB constituent protein, interaction with the IκB (Inhibitor of κB) protein and binding to the target gene promoter. It also contains a Nuclear Localization Signal (NLS) to move into the nucleus and act as a transcription factor.
As shown in FIG. 2 A of FIG. 2, when the incubation time was adjusted to 6 hours with RAW264.7 cells, the expression of NF-κB gene was measured by treating 2 μg / ml of LPS with NF-κB expression, KB protein levels (Fig. 2 (A)). On the other hand, it was found that the antifungal ethanol extract decreased the protein level of NF-κB in a dose-dependent manner when LPS was treated (FIG. 2B). These results suggest that NF-κB is involved in the signaling pathway of NO production, and NF-κB activation is reduced by the antimutagenic ethanol extract powder, and IκB, which is a transcription factor, is decreased and binding to the nuclear promoter is inhibited. Which means that NO production is reduced by inactivation.
Example 3: Antimutagenic extract from vascular endothelial cells NO Production activity and mechanism research
(1) Measurement of NO production in mouse vascular endothelial cells (MOVAS, Mouse vascular endothelial cell)
Nitric Oxide promotes vascular endothelial protection, strong antioxidant production, circulatory system, immune system, nervous system, etc., and has a function of signaling to all the organs of the human body. As a result, NO production was significantly higher in 100 ㎍ / ㎖ HA (100 ㎍ / ㎖) and 100 ㎍ / ㎖ (100 ㎍ / ㎖) treated with MOVAS than in the control group (Fig. 3).
(2) NF-κB signal transduction mechanism in murine vascular endothelial cells (MOVAS)
As shown in Fig. 4A, the NF-κB expression was observed in MOVAS cells for 12 hours. The expression of NF-κB was detected in 10, 50 ㎍ / ㎖ of firefly luciferase (HA) 10, and 50 ㎍ / ㎖, respectively, compared to the control group. IκB expression was increased in 10, 50, 100 ㎍ / ㎖ HA treated group and 10, 50 ㎍ / ㎖ HB treated group compared to the control group.
As shown in Fig. 4B, NF-κB expression was observed in 10, 50 ㎍ / ㎖ HA treated group and 10, 50 ㎍ / ㎖ HB treated group in the control group And 10 ㎍ / ㎖ of HA treatment group, 10, 50 ㎍ / ㎖ of HB treatment group and 10, 50, 100 ㎍ / ㎖ HB treatment group were significantly increased compared to the control group.
These results indicate that NF-κB is involved in the signaling pathway of NO production and NF-κB activation is decreased by the antimycotic extract, and IκB, which is a transcription factor, increases and binds to the nuclear promoter, The output is interpreted as indicating an increase.
(3) NF-κB signal transduction mechanism in human vascular endothelial cells (HUVEC) by antler extract
As shown in FIG. 5, when NF-κB expression was observed in HUVEC cells for 12 hours, 10, 50 μg / ml of HA treatment group and 10, 50 and 100 μg / ml of HB treatment group were decreased compared to the control group IκB expression was increased in 10, 50, 100 ㎍ / ㎖ HA treated group and 10, 100 ㎍ / ㎖ HB treated group compared to the control group.
These results suggest that NF-κB is involved in NO production by HUVEC cells. NF-κB activation is reduced by the antimycotic extract, and IκB, which is a transcription factor, binds to the nuclear promoter. .
(4) Production activity of endothelial nitric oxide synthase (eNOS) in vascular endothelial cells by firefly extract
In the mouse vascular endothelial cell MOVAS and human vascular endothelial cell HUVEC, the production of NO was increased by the antimycotic extract. There were two types of vascular endothelial cell eNOS, activated and inactivated, and eNOS (NO) can be produced only in the activated form, demonstrating a mechanism of increasing NO production and NF-κB phosphorylation in an antimycotic extract.
FIG. 6 shows the expression of eNOS (endothelial NOS) gene in the vascular endothelial cells MOVAS and HUVEC by the antiserum extract. As a result, eNOS mRNA gene expression in human HUVEC cells was increased in a concentration - dependent manner in the ethanol extract of Fusarium oxysporum, although there was no significant difference in MOVAS cells.
Claims (5)
(b) adding an aqueous ethanol solution to the firewood taken out in step (a), extracting it, filtering and separating the ethanol extract;
(c) separating the ethanol extract of step (b) and adding water and proteolytic enzyme to the remaining firewood to extract the extract;
(d) mixing the extracted extract of step (c) and the ethanol extract of step (b), filtering and drying; And
(e) adding dextrin and water to the dry antler extract of step (d) and spray-drying the antler extract; and (e) treating the antler extract of step (d).
(a) immersing the dried firefly in an aqueous alkaline solution having a pH of 8 to 9 for 50 to 70 minutes and then taking out the same;
(b) adding an aqueous 45 to 55% (v / v) ethanol solution to the fire ants taken in step (a), extracting the mixture at 50 to 70 ° C for 8 to 12 hours, filtering and separating the ethanol extract;
(c) extracting the ethanol extract of step (b), adding water and proteolytic enzyme to the remaining anthrax extract, extracting it at 40 to 50 ° C for 65 to 80 hours while maintaining the pH at 8 to 9;
(d) mixing the extracted extract of step (c) and the ethanol extract of step (b), filtering and drying; And
(e) adding dextrin and water to the dry antimycotic extract of step (d) to adjust the brix to 25 to 35 brix, bringing the temperature to 170 to 190 DEG C and the air temperature to 100 to 120 DEG C at a rate of 0.2 to 0.4 L / Wherein the method comprises the step of spray-drying and the step of spray-drying.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150112211A KR101552821B1 (en) | 2015-08-10 | 2015-08-10 | Enzymatic hydrolized Formica truncicola extract powder having vasodilatation, sexual function improvement and anti-inflammatory effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150112211A KR101552821B1 (en) | 2015-08-10 | 2015-08-10 | Enzymatic hydrolized Formica truncicola extract powder having vasodilatation, sexual function improvement and anti-inflammatory effect |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101552821B1 true KR101552821B1 (en) | 2015-09-16 |
Family
ID=54248179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150112211A KR101552821B1 (en) | 2015-08-10 | 2015-08-10 | Enzymatic hydrolized Formica truncicola extract powder having vasodilatation, sexual function improvement and anti-inflammatory effect |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101552821B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102601729B1 (en) * | 2023-06-20 | 2023-11-13 | (주)나일랜드 | Manufacturing method composition for improving male sexual function |
-
2015
- 2015-08-10 KR KR1020150112211A patent/KR101552821B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102601729B1 (en) * | 2023-06-20 | 2023-11-13 | (주)나일랜드 | Manufacturing method composition for improving male sexual function |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10471114B2 (en) | Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome | |
EP2517711B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
US8518462B2 (en) | Compound comprising extracts or fractions of chrysanthemum boreale makino having anti-inflammation activity | |
KR101870960B1 (en) | Composition for preventing or treating of colitis disease comprising Lactobacillus sakei K040706 as an active ingredient | |
KR20150120880A (en) | Pharmaceutical composition for preventing or treating chronic obstructive pulmonary diseases(COPD), comprising an extract, a fraction or a compounds derived from Pistacia weinmannifolia | |
KR101662719B1 (en) | A composition for the prevention or treatment of prostate-related disease comprising Ponciri Fructus extract | |
Alam et al. | Mycotoxins in environment and its health implications | |
JP5799082B2 (en) | 用途 New use of yellow or yellow extract | |
KR101217181B1 (en) | Composition for preventing, improving or treating atopyic dermatitis comprising tannic acid and quercetin as an active ingredient | |
KR101552821B1 (en) | Enzymatic hydrolized Formica truncicola extract powder having vasodilatation, sexual function improvement and anti-inflammatory effect | |
JP2007291081A (en) | Composition having bone resorption inhibition-related effect | |
KR101604347B1 (en) | Pharmaceutical composition comprising an extract or a fraction of Pistacia weinmannifolia J. Poiss. Ex Franch for preventing or treating inflammatory-related diseases | |
KR102102267B1 (en) | Pharmaceutical and fool composition comprising lactic acid bacteria complex and N-acetylglucosamin as an active ingredient for preventing or treating skin moisturizing, osteoporosis | |
KR102404641B1 (en) | Composition for preventing, improving or treating respiratory disease | |
AU2017365116B2 (en) | Oral compositions comprising beta-escin for reducing acetaldehyde toxicity | |
KR20200120549A (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
KR101629642B1 (en) | Food composition, pharmaceutical composition, animal medicine and feed composition against fatty liver with piperlongumine | |
KR20110138732A (en) | Composition comprising extracts of cedrela sinensis for anti-inflammatory activity | |
KR101532307B1 (en) | Pharmaceutical compositions having anti-metastasis activity comprising extract of bambusae caulis in taeniam | |
KR102190772B1 (en) | Method for producing soybean paste and soy sauce adding Rhus verniciflua fermented extract | |
JP5279163B2 (en) | Anti-aging agent, platelet aggregation inhibitor, antioxidant, antiallergic agent and food and drink | |
KR20160149664A (en) | Composition for preventing, improving or treating of arthritis comprising boswellia serrata extract, grape seed extract and juniperus communis extract as effective component | |
KR20220064019A (en) | A Method for Preparing An Extract of Antarctic Lichen Amandinea sp. and Composition Comprising the Extract of Amandinea sp. | |
KR20230001824A (en) | Compositions for prevention and treatment of inflammatory bowel disease comprising of extract of Puer Tea | |
KR20220084732A (en) | Composition for preventing, improving or treating of androgen-dependent disorders comprising alginate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180719 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190703 Year of fee payment: 5 |